Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesArtelo Biosciences Inc

Artelo Biosciences Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.91 USD -0.20 ( 9.69%)
Last update at 2026-11-06T21:00:00Z
VOLUME
16280
Market Cap
3.80M

Momentum Score

…

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.91
Low
2.23
High
52 Week Price Range
2.96
Low
85.80
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Artelo Biosciences Inc is a development-stage biotechnology company focused on therapies leveraging cannabinoid science and synthetic small molecules. Long-term growth may be driven by development progress, regulatory milestones and partnerships, which may appeal to investors seeking exposure to novel therapeutic approaches.

Key risks include clinical and regulatory failure, high cash burn with likely need for additional financing, and limited liquidity and volatility typical of small-cap biotechs.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.12
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-0.54
ROE
-1625.11%
Net Debt
0.09M
ROCE
1020.51%
Diluted EPS TTM
-33.97

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-08-31 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-08-31 2022-12-31
Income before tax -12.88M -9.83M -9.29M -10.08M -10.08M
Net income -12.88M -9.83M -9.29M -9.87M -9.87M
Selling general administrative 5.98M 4.12M 4.23M 5.96M 5.96M
Ebit -12.69M -10.11M - -10.29M -10.29M
Ebitda -12.54M -10.11M - -10.29M -10.29M
Depreciation and amortization 0.15M - - 0.00M 0.00M
Operating income -11.40M -10.11M -9.93M -10.29M -10.29M
Other operating expenses 11.40M 10.11M - 10.29M 10.29M
Interest expense 0.19M 0.00M 0.00M 0.01M 0.01M
Tax provision 0.00M 0.00M 0.00M - 0.00M
Interest income - - 0.00M - 0.00M
Net interest income -0.28M 0.00M 0.00M - -0.00M
Income tax expense - - - -0.21M -0.21M
Total revenue 0.00M 0.00M 0.00M - 0.00M
Total operating expenses 11.40M 10.11M 9.93M 10.29M 10.29M
Total other income expense net -1.48M 0.28M 0.64M 0.20M 0.20M
Net income from continuing ops -12.88M -9.83M -9.29M - -10.29M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-08-31 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-08-31 2022-12-31
Total assets 2.80M 4.70M 13.04M 20.42M 20.42M
Intangible assets 2.04M 2.04M 2.04M 2.04M 2.04M
Other current assets 0.10M 0.22M 0.55M 0.79M 0.79M
Total liab 4.07M 1.84M 1.29M 1.02M 1.02M
Total stockholder equity -1.27M 2.86M 11.75M 19.40M 19.40M
Other current liab 3.38M 0.06M - 0.05M -0.85M
Common stock 0.00M 0.00M - 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M - 0.00M
Retained earnings -63.02M -50.14M -40.31M -31.02M -31.02M
Cash 0.60M 2.34M 2.81M 6.89M 6.89M
Total current liabilities 4.04M 1.77M 1.29M 1.00M 1.00M
Net debt 0.09M -2.23M - -6.83M -6.83M
Short term debt 0.66M 0.04M - 0.04M 0.04M
Short long term debt 0.61M - - - -
Short long term debt total 0.69M 0.10M - 0.06M 0.06M
Other stockholder equity 62.01M 53.19M - 50.67M 50.67M
Total current assets 0.69M 2.56M 10.98M 18.32M 18.32M
Long term investments - - - - 0.00M
Short term investments - 0.00M 7.61M 10.64M 10.64M
Accounts payable 3.04M 1.68M 1.24M 0.91M 0.91M
Accumulated other comprehensive income -0.27M -0.20M - -0.25M -0.25M
Non currrent assets other 0.00M 0.00M 0.00M 0.00M 0.00M
Non current assets total 2.11M 2.14M 2.06M 2.10M 2.10M
Capital lease obligations 0.07M 0.10M 0.02M - 0.02M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-08-31 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-08-31 2022-12-31
Investments -0.06M 7.77M 3.51M - 4.90M
Total cashflows from investing activities -0.06M 7.77M - - -
Net borrowings 0.58M 0.00M - - -
Total cash from financing activities 6.87M 0.11M 0.57M -0.04M -0.04M
Net income -12.88M -9.83M -9.29M -10.08M -10.08M
Change in cash -1.74M -0.48M -4.07M -5.27M -5.27M
Begin period cash flow 2.34M 2.81M 6.89M 12.16M 12.16M
End period cash flow 0.60M 2.34M 2.81M 6.89M 6.89M
Total cash from operating activities -8.52M -8.35M -8.21M -8.01M -8.01M
Issuance of capital stock 6.15M 0.11M 0.57M - 0.54M
Depreciation 0.15M - - - -
Other cashflows from investing activities -0.06M - - - -
Other cashflows from financing activities 6.87M - - 0.04M 2.96M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 1.75M 0.94M 0.70M -0.17M -0.17M
Stock based compensation 1.14M 0.82M 1.02M 2.46M 2.46M
Other non cash items 1.32M -0.28M - -0.21M -0.21M
Free cash flow -8.52M -8.35M -8.21M -8.01M -8.01M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
ARTL
Artelo Biosciences Inc		 -0.20
9.69%		 1.91 - - - 0.50 1.22
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Artelo Biosciences Inc

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

505 Lomas Santa Fe, Solana Beach, CA, United States, 92075

858 925 7049

https://artelobio.com

7

Name Title Year Born
Mr. Gregory D. Gorgas M.B.A. Pres, CEO, CFO, Treasurer, Sec. & Director 1963
Dr. Andrew Yates Ph.D. Sr. VP & Chief Scientific Officer NA
Dr. Steven D. Reich Chief Medical Officer 1946
Mr. Jason H. Baybutt Sr. VP of Fin. 1972
Mr. Gregory D. Gorgas M.B.A. President, CEO, CFO, Treasurer, Secretary & Director 1963
Dr. Andrew Yates Ph.D. Senior VP & Chief Scientific Officer NA
Mr. Jason H. Baybutt Senior Vice President of Finance 1972
Mr. Gregory D. Gorgas M.B.A. President, CEO, Secretary & Director 1963
Dr. Steven D. Reich M.D. Chief Medical Officer 1946

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…